Phoenix PharmaLabs

Phoenix PharmaLabs

Testing the Waters
Growth Stage

Addressing the opioid crisis by developing potent, safe, non-addictive painkillers.

Addressing the opioid crisis by developing potent, safe, non-addictive painkillers.

Overview

Raised to Date: Raised: $0

Total Commitments ($USD)

Platform

Netcapital

Start Date

12/23/2020

Close Date

Testing the Waters

Min. Goal
Funded
Max. Goal
Funded
Min. Investment

$99

Security Type

Equity - Common

Series

Seed

SEC Filing Type

Test the Waters    Open SEC Filing

Price Per Share

$1.00

Pre-Money Valuation

$26,790,283

Rolling Commitments ($USD)

Status
Funded
Reporting Date

01/30/2021

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$0

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Logos provided by Clearbit
Year Founded

2002

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B2C

Margin

High

Capital Intensity

High

Location

Woods Cross, Utah

Business Type

Growth

Company Website

Phoenix PharmaLabs, with a post-money valuation of $26,790,283, iis Testing the Waters on NetCapital. The company is a preclinical drug discovery company dedicated to the development of potent, safe, non-addictive treatments for pain and addiction. John Lawson, PH.D. and Lawrence Toll, PH.D. founded Phoenix PharmaLabs. The crowdfunding round has a minimum raise of $10,000 and a maximum raise of $1,070,000. Phoenix PharmaLabs lead drug, PPL-103, has demonstrated in animal studies that it is a very potent painkiller (10x more potent than morphine), and is non-addictive, does not produce withdrawal, does not cause death from overdose at elevated doses, and causes no constipation.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Phoenix PharmaLabs 06/17/2021 Netcapital $26,790,283 $1,065,500 Equity - Common Funded RegCF
Phoenix PharmaLabs 01/29/2021 Netcapital $26,790,283 $0 Equity - Common Funded Test the Waters
Phoenix PharmaLabs 03/29/2019 Netcapital $23,136,335 $1,102,553 Equity - Common Funded RegCF / RegD 506(c)
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Phoenix PharmaLabs on Netcapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $26,790,283
Price per Share: $1.00

Follow company

Follow Phoenix PharmaLabs on Netcapital
View on Netcapital (Testing the Waters)
Deal Analytics
Deal Considerations

Buy Phoenix PharmaLabs's Deal Report

Warning: according to the close date for this deal, Phoenix PharmaLabs may no longer be accepting investments.

Phoenix PharmaLabs Deal Report

Get KingsCrowd’s comprehensive report on Phoenix PharmaLabs including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Phoenix PharmaLabs is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Phoenix PharmaLabs deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge